

A Workshop on Biomarkers and Other Pre-clinical Diagnostics of Alzheimer's Disease

Committee

Reisa A. Sperling

Chair

Reisa A. Sperling (Chair) is a professor of neurology at Harvard Medical School, and is the director of the Center for Alzheimer's Research and Treatment at Brigham and Women's Hospital and Massachusetts General Hospital. Her research is focused on the detection and treatment of Alzheimer's disease at the presymptomatic or "preclinical" stage. She is the co-principal investigator of the Harvard Aging Brain Study, and the NIH funded Alzheimer Clinical Trial Consortium (ACTC). She chaired the 2011 NIA-Alzheimer's Association workgroup to develop guidelines for the study of "Preclinical Alzheimer's disease." She co-leads the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) Study, the first of its kind prevention trial in preclinical AD, and is currently launching two new AD prevention trials (AHEAD 3-45 Study) with the ACTC in 2020. She has authored over 300 peer-reviewed publications related to aging and Alzheimer's disease. She received her doctorate in medicine from Harvard Medical School.

David A. Bennett

Member

David A. Bennett is the director of the Rush Alzheimer's Disease Center and the Robert C. Borwell Professor of Neurological Sciences. As director, he leads a multidisciplinary research and clinical center that studies a wide range of common chronic conditions of aging, including Alzheimer's disease, stroke, Parkinson's disease, other neurodegenerative diseases, sleep, neuro- and behavior economics, decision making and well-being. His research ranges from community-based epidemiologic studies that incorporate genomics, imaging and biomedical devices, to phase I to phase IV clinical trials. Notable studies include the Rush Alzheimer's Disease Core Center, the Religious Orders Study, and the Rush Memory and Aging Project. He also directs the Regional Alzheimer's Disease Assistance Center for Northern Illinois and serves on numerous national and international advisory and editorial boards. He is currently a member of the National Advisory Council on Aging for the National Institutes of Health. He received his doctorate in medicine from Rush Medical College, Chicago, IL.

Nathaniel A. Chin

Member

Nathaniel A. Chin is a board-certified internist, geriatrician, and assistant professor (CHS) of geriatric medicine at the University of Wisconsin School of Medicine and Public Health. During his internal medicine residency at the University of California San Diego, his father was diagnosed with Alzheimer's disease dementia. His father's condition influenced him to pursue a career as a geriatrician and scientist focused on cognitive impairment, specifically Alzheimer's disease. After creating and completing a geriatric-based dementia fellowship at UW-Madison, he joined the Wisconsin Alzheimer's Disease Research Center (ADRC), Wisconsin Registry for Alzheimer's Prevention Study (WRAP), and University of Wisconsin Hospital and Clinics. He is currently the medical director of the ADRC and WRAP, where he is focused on biomarker disclosure to healthy and impaired research participants (2 current NIA/NIH funded grants) and continues to study the cognitive impact of addressing modifiable risk factors through lifestyle interventions. He sees patients in his memory clinic 2 days each week, and has developed and implemented a chronic care model focused on palliative care post-diagnosis. He also serves as the associate director of the Geriatric Memory Program. He received his doctorate in medicine from the University of Wisconsin School of Medicine and Public Health.

Jessica Langbaum

Member

Jessica Langbaum is the co-director of the Alzheimer's Prevention Initiative (API) at Banner Alzheimer's Institute where she also directs the Alzheimer's Prevention Registry and its GeneMatch program. Her research is focused on (1) establishing the science of participant recruitment and retention for Alzheimer's prevention studies, including designing and executing participant recruitment registries, (2) assessing the impact of genetic testing and risk disclosure, in particular disclosure of APOE and other biomarker (e.g., brain amyloid) results, and (3) designing and executing preclinical AD treatment studies, including developing sensitive, novel composite cognitive test scores for use as primary endpoint measures. She has published numerous papers on these topics. She serves on several national and international advisory boards, she participated previously in two National Academies workshops (The National Academies' Workshop on Return of Research Results; Enabling Precision Medicine: The Role of Genetics in Clinical Drug Development). She received her Ph.D. in psychiatric epidemiology from the Johns Hopkins University Bloomberg School of Public Health. She completed a post-doctoral research fellowship in brain imaging and Alzheimer's disease clinical trial design at Banner Alzheimer's Institute.